3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Burkitt Lymphoma
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Leukemia, Biphenotypic, Acute
7
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
3
Leukemia, Myeloid, Accelerated Phase
3
Blast Crisis
3
Lymphoma, Mantle-Cell
2
Down Syndrome
2
Blastic Plasmacytoid Dendritic Cell Neoplasm
2
Renal Pelvis and Ureter Urothelial Carcinoma
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Rituximab
40
Cyclophosphamide
36
Prednisone
24
Doxorubicin
23
Magnetic Resonance Spectroscopy
20
Vincristine
19
Gemcitabine
18
Specimen Handling
17
Lenalidomide
17
Biopsy
15
Oxaliplatin
14
polatuzumab vedotin
13
obinutuzumab
11
glofitamab
11
ibrutinib
10
fludarabine
8
Etoposide
8
Dexamethasone
8
CT-P10
8
prednylidene
7
deltacortene
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
7
venetoclax
6
tafasitamab
6
pembrolizumab
6
Prednisolone
6
fludarabine phosphate
5
acalabrutinib
5
R-CHOP protocol
5
Immunotherapy, Adoptive
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
merphos
×
90 days
×
Clear all
No trials found.